Tertiary lymphoid structures (TLS) are increasingly recognized to have roles in cancer. Within tumor microenvironments (TME), TLS can arise as ectopic lymphoid organs containing aggregates of lymphocytes and antigen-presenting cells in response to inflammation. Dense in immune infiltrates of CD8 and CD4 T cells as well as dendritic cells and B cells, TLS are thought to facilitate immune infiltration into the TME thereby aiding in anti-tumor responses and clinical benefit. They are seen in multiple cancer types drawing attention to their use as prognostic factors and as biomarkers of response. Immuno-therapies, including checkpoint blockade targeting the programmed cell death protein 1 (PD-1) pathway have also been linked to the enrichment of TLS. However, their development during treatment or progression of cancer remains to be understood.
The goal of this research topic is to create a collection of original research and review articles that focus on and elucidate the mechanisms leading to TLS development and cross-talk signaling in solid tumor malignancies during cancer progression and over the course of treatment with immunotherapies. This includes findings of biomarkers linked to these changes.
We would like to encourage submissions from cancer immunology research fields, including basic science, translational research, and clinical investigations in the form of original research, review, and perspectives. Submissions can include (but are not limited to:
- TLS development during treatment with immunotherapy
- TLS as biomarkers of response
- Novel roles of TLS in anti-tumor responses
- Role of TLS in patient survival
- Predicative role of TLS
- Novel models of TLS development
- Mechanistic studies of TLS development or generation
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Topic editor Antoine Italiano is on the advisory board for Advisory Board: Bayer, BMS, Merck, MSD, Roche, AstraZeneca, Parthenon, Domain Therapeutics, and Daiichi Sankyo. He has also received financial support from Bayer, BMS, Merck, MSD, Roche, AstraZeneca, Parthenon, Domain Therapeutics, Daiichi Sankyo, Novartis, and Chugai. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Tertiary lymphoid structures (TLS) are increasingly recognized to have roles in cancer. Within tumor microenvironments (TME), TLS can arise as ectopic lymphoid organs containing aggregates of lymphocytes and antigen-presenting cells in response to inflammation. Dense in immune infiltrates of CD8 and CD4 T cells as well as dendritic cells and B cells, TLS are thought to facilitate immune infiltration into the TME thereby aiding in anti-tumor responses and clinical benefit. They are seen in multiple cancer types drawing attention to their use as prognostic factors and as biomarkers of response. Immuno-therapies, including checkpoint blockade targeting the programmed cell death protein 1 (PD-1) pathway have also been linked to the enrichment of TLS. However, their development during treatment or progression of cancer remains to be understood.
The goal of this research topic is to create a collection of original research and review articles that focus on and elucidate the mechanisms leading to TLS development and cross-talk signaling in solid tumor malignancies during cancer progression and over the course of treatment with immunotherapies. This includes findings of biomarkers linked to these changes.
We would like to encourage submissions from cancer immunology research fields, including basic science, translational research, and clinical investigations in the form of original research, review, and perspectives. Submissions can include (but are not limited to:
- TLS development during treatment with immunotherapy
- TLS as biomarkers of response
- Novel roles of TLS in anti-tumor responses
- Role of TLS in patient survival
- Predicative role of TLS
- Novel models of TLS development
- Mechanistic studies of TLS development or generation
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Topic editor Antoine Italiano is on the advisory board for Advisory Board: Bayer, BMS, Merck, MSD, Roche, AstraZeneca, Parthenon, Domain Therapeutics, and Daiichi Sankyo. He has also received financial support from Bayer, BMS, Merck, MSD, Roche, AstraZeneca, Parthenon, Domain Therapeutics, Daiichi Sankyo, Novartis, and Chugai. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
